HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Saralasin (Saralasin Acetate)

An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II.

Also Known As:

Saralasin Acetate; (Sar(1),Ala(8))ANGII; (Sar1,Val5,Ala8)Angiotensin II; 1-Sar-8-Ala-angiotensin II; P-113; P-113 Acetate; Sar-Arg-Val-Tyr-Val-His-Pro-Ala; Saralasin Acetate, Anhydrous; Saralasin Acetate, Hydrated; angiotensin II, Sar(1)-Ala(8)-; angiotensin II, sarcosyl(1)-alanine(8)-; 1 Sar 8 Ala Angiotensin II; 1 Sarcosine 8 Alanine Angiotensin II; Acetate, Hydrated Saralasin; Angiotensin II, 1-Sar-8-Ala; Angiotensin II, 1-Sarcosine-8-Alanine; Anhydrous Saralasin Acetate; Hydrated Saralasin Acetate; Sar Arg Val Tyr Val His Pro Ala; 1-Sar-8-Ala Angiotensin II; 1-Sarcosine-8-Alanine Angiotensin II; Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-

Networked: 271 relevant articles (8 outcomes, 26 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Friden, P: 3 articles (12/2002 - 05/2001)
2.	Aho, Heikki: 2 articles (04/2005 - 02/2004)
3.	Laine, Jukka: 2 articles (04/2005 - 02/2004)
4.	Zagariya, Alexander: 2 articles (04/2005 - 02/2004)
5.	Vidyasagar, Dharmapuri: 2 articles (04/2005 - 02/2004)
6.	Tsang, Siu Wai: 2 articles (04/2003 - 03/2003)
7.	Leung, Po Sing: 2 articles (04/2003 - 03/2003)
8.	Che, Chun Tao: 2 articles (04/2003 - 03/2003)
9.	Wong, Tung Po: 2 articles (04/2003 - 03/2003)
10.	Ip, Siu Po: 2 articles (04/2003 - 03/2003)

Related Diseases

1.	Hypertension (High Blood Pressure) 11/01/1979 - "The mean decline in diastolic blood pressure to saralasin in the subnormal adrenal responsive patients (-15 +/- 3 mm Hg) was significantly greater than in the normal adrenal responsive group (-3 +/- 2 mm Hg) (P < 0.02).It is concluded that patients with HREH are not a homogeneous population; approximately one-third have AII-dependent hypertension. " 02/01/1986 - "Taking into consideration international studies our results confirm that the Saralasin test, taking into account strongly standardized methodical prerequisites, is suited to objectify a participation of the RAAS in the hypertension pathogenesis, without, however, thus making an absolutely reliable evidence concerning the etiology of hypertension. " 05/01/1980 - "Studies were performed to determine whether the hypertension in this disorder could be corrected by saralasin infusion. " 11/01/1979 - "The AII competitive inhibitor, saralasin (0.3-30 mug/kg per min) was then infused to study the occurrence of angiotensinogenic hypertension in both HREH subgroups. " 12/01/1977 - "The results cast doubts on the clinical usefulness of saralasin in the investigation of patients with hypertension, when studied in the conditions of the present study."
2.	Hemorrhage 02/01/2002 - "There was a significant reduction in the change from baseline to Day 22 in bleeding on probing in the 0.01% P-113 treatment group of the intent to treat population (p=0.049). " 05/01/2001 - "Similar trends were noted for changes in the % of sites with bleeding on probing in the 0.01% P-113 group. " 01/01/1990 - "MC did not affect the blood pressure recovery; however, saralasin reduced it to the post-hemorrhage levels. " 06/01/1986 - "However, injection of converting enzyme inhibitor (SQ 20881) or saralasin in order to block endogenous ANG II did not attenuate either basal or hemorrhage-stimulated drinking in the marine fish." 03/01/1985 - "Intravenous saralasin did not blunt the response to hemorrhage. "
3.	Pancreatitis 03/28/2003 - "These data indicate that administration of saralasin but not ramiprilat could be protective against acute pancreatitis and that activation of pancreatic RAS in acute pancreatitis may play a role in pancreatic tissue injury." 04/01/2003 - "These data suggest that prophylactic administration of saralasin can ameliorate the oxidative stress and tissue injury in cerulein-induced pancreatitis. " 04/01/2003 - "In the current study we hypothesized that inhibition of this renin-angiotensin system by saralasin, a nonspecific antagonist for angiotensin II receptor, could attenuate the severity of cerulein-induced pancreatitis. " 04/01/2003 - "Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis." 03/28/2003 - "Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis."
4.	Gingivitis 05/01/2001 - "There was a significant reduction in plaque (p=0.046) and a reduction in gingivitis (p=0.086) for subjects using 0.01% P-113 mouthrinse. " 05/01/2002 - "Animal studies and human clinical trials showed that P-113 has potential in preventing the development of gingivitis, with no adverse side effects. " 02/01/2002 - "During this time, the safety, anti-gingivitis, and anti-plaque effects of P-113 were evaluated. " 05/01/2001 - "During this time, the safety, anti-plaque, and anti-gingivitis effects of P-113 were evaluated. " 05/01/2001 - "P-113, a 12 amino acid histatin-based peptide, was evaluated in a mouthrinse formulation for safety, prevention of the development of experimental gingivitis, and for its effects on periodontal flora. "
5.	Coronary Occlusion 10/01/1992 - "Saralasin decreased the incidence of ventricular fibrillation during coronary occlusion (from 44% in the vehicle treated group to 0% in the saralasin treated group, p = 0.0412). "

Related Drugs and Biologics

1.	Angiotensins
2.	Angiotensin Receptors (Angiotensin II Receptor)
3.	Gases
4.	Carbon Monoxide
5.	ramiprilat
6.	Angiotensin II
7.	Renin
8.	Captopril (Capoten)
9.	Caerulein (Ceruletide)
10.	Sodium

Related Therapies and Procedures

1.	Surgical Instruments (Clip)
2.	Transplants (Transplant)
3.	Intravenous Injections
4.	Nephrectomy
5.	Intravenous Infusions